Inhibition of angiogenesis in the treatment of tumors

Archivum Immunologiae et Therapiae Experimentalis

Volumn 49, Issue 1, 2001, Pages 27-31

  Ostrowski, Kazimierz ^a,b   Kinsner, Agnieszka ^b  

^a POLISH ACADEMY OF SCIENCES   (Poland)

^b MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

Angiogenesis; Cancer treatment; Inhibitors

Indexed keywords

ANTINEOPLASTIC AGENT; GROWTH INHIBITOR; MATRIX METALLOPROTEINASE; PROTEINASE INHIBITOR;

ANIMAL; DRUG ANTAGONISM; EXPERIMENTAL NEOPLASM; HUMAN; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); REVIEW; VASCULARIZATION;

ANIMALS; ANTINEOPLASTIC AGENTS; GROWTH INHIBITORS; HUMANS; MATRIX METALLOPROTEINASES; NEOPLASMS; NEOPLASMS, EXPERIMENTAL; NEOVASCULARIZATION, PATHOLOGIC; PROTEASE INHIBITORS;

EID: 0035220518     PISSN: 0004069X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (34)

1. BOEHM T., FOLKMAN J., BROWDER T. and O'REILLY M. S. (1997): Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature, 390, 404-407.
2. BOEHM T., O'REILLY M. S., KEOUGH K., SHILOACH J., SHAPIRO R. and FOLKMAN J. (1998): Zinc-binding of endostatin is essential for its antiangiogenic activity. Biochem. Biophys. Res. Commun., 252, 190-194.
3. BROWN P. D. (1997): Matrix metalloproteinase inhibitors in the treatment of cancer. Med. Oncol., 14, 1-10.
4. BURG M. A., PASQUALINI R., ARAP W., RHOUDAHTI E., STALLCUP R. and FOLKMAN J. (1999): NG2 proteoglicans binding peptides target tumor neovasculature. Cancer Res., 59, 2869-2874.
5. CHESON B. D., PHILLIPS P. H., PLUDA J. M. and CHRISTIAN M. (1995): Clinical trials referral resource. Clin. Trials Suramin. Oncol., 9, 161-163.
6. FOLKMAN J. (1972): Anti-angiogenesis: new concept for therapy of solid tumors. Ann. Surg., 175, 409-416.
7. FONG T. A., SHAWVER L. K., SUN L., TANG C., APP H., POWELL T. J., KIM Y. H., SCHRECK R., WANG X., RISAU W., ULLRICH A., HIRTH K. P. and MCMAHON G. (1999): SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumour vascularisation, and growth of multiple tumour types. Cancer Res., 59, 99-106.
8. FUJIMOTO J., HORI M., ICHIGO S., HIROSE R., SAKAGUCHI H. and TAMAYA T. (1997): Plausible novel therapeutic strategy of uterine endometrial cancer with reduction of basic fibroblast growth factor secretion by progestin and O-(chloroacetyl-carbamoyl) fumagillol (TNP-470; AGM-1470). Cancer Lett., 113, 187-194.
9. GIBALDI M. (1998): Regulating angiogenesis: a new therapeutic strategy. J. Clin. Pharmacol., 38, 898-903.
10. GIMBRONE M. A. JR., LEAPMAN S. B., COTRAN R. S. and FOLKMAN J. (1972): Tumor dormancy in vivo by prevention of neovascularization. J. Exp. Med., 136, 261-276.
11. GOKASLAN Z. L., CHINTALA S. K., YORK J. E., BOYAPATI V., JASTI S., SAWAYA R., FULLER G., WILDRICK D. M., NICOLSON G. L. and RAO J. S. (1998): Expression and role of matrix metalloproteinases MMP-2 and MMP-9 in human spinal column tumors. Clin. Exp. Metastasis, 16, 721-728.
12. GOMEZ D. E., ALONSO D. F., YOSHIJI H. and THORGEIRSSON U. P. (1997): Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur. J. Cell Biol., 74, 111-122.
13. GORSKI D. H., MAUCERI H. J., SALLOUM R. M., GATELY S., HELLMAN S., BECKETT M. A., SUKHATME V. P., SOFF G. A., KUFE D. W. and WEICHSELBAUM R. R. (1998): Potentiation of the antitumour effect of ionising radiation by brief concomitant exposures to angiostatin. Cancer Res., 58, 5686-5689.
14. HUDLICKA O. (1991): What makes blood vessels grow? J. Physiol., 444, 1-24.
15. KAKEJI Y. and TEICHER B. A. (1997): Preclinical studies of the combination of angiogenic inhibitors with cytotoxic agents. Invest. New Drugs., 15, 39-48.
16. KERBEL R. S. and HAWLEY R. G. (1995): Interleukin 12: newest member of the antiangiogenesis club. J. Int. Cancer Inst., 87, 557-559.
17. KERR J. S., WEXLER R. S., MOUSA S. A., ROBINSON C. S., WEXLER E. J., MOHAMED S., VOSS M. E., DEVENNY J. J., CZERNIAK P. M., GUDZELAK A. JR. and SLEE A. M. (1999): Novel small molecule alpha v integrin antagonists: comparative anti-cancer efficacy with known angiogenesis inhibitors. Anticancer Res., 19, 959-968.
18. KLAGSBRUN M. and D'AMORE P. A. (1996): Vascular endothelial growth factor and its receptors. Cytokine Growth Factor Rev., 7, 259-270.
19. KOHN E. C., REED E., SAROSY G., CHRISTIAN M., LINK C. J., COLE K., FIGG W. D., DAVIS P. A., JACOB J., GOLDSPIEL B. and LIOTTA L. A. (1996): Clinical investigation of a cytostatic calcium influx inhibitor in patients with refractory cancers. Cancer Res., 56, 569-573.
20. MAUCERI H. J., HANNA N. N., BECKETT M. A., GORSKI D. H., STABA M. J., STELLATO K. A., BIGELOW K., HEIMANN R., GATELY S., DHANABAL M., SOFF G. A., SUKHATME V. P., KUFE D. W. and WEICHSELBAUM R. R. (1998): Combined effects of angiostatin and ionizing radiation in antitumour therapy. Nature, 394, 287-291.
21. NEMUNAITIS J., POOLE C., PRIMROSE J., ROSEMURGY A., MALFETANO J., BROWN P., BERRINGTON A., CORNISH A., LYNCH K., RASMUSSEN H., KERR D., Cox D. and MILLAR A. (1998): Combined analysis of studies of the effects of the matrix metalloproteinase inhibitor Marimastat on serum tumour markers in advanced cancer: selection of a biologically active and tolerable dose for longer-term studies. Clin. Cancer Res., 4, 1101-1109.
22. O'REILLY M. S., BOEHM T., SHING Y., FUKAI N., VASIOS G., LANE W. S., FLYNN E., BIRKHEAD J. R., OLSEN B. R. and FOLKMAN J. (1997): Endostatin: an endogenous inhibitor of angiogenesis and tumour growth. Cell, 88, 277-285.
23. O'REILLY M. S., HOLMGREN L., CHEN C. and FOLKMAN J. (1996): Angiostatin induces and sustains dormancy of human primary tumours in mice. Nat. Med., 2, 689-692.
24. POLETTE M. and BIREMBAUT P. (1998): Membrane-type metalloproteinases in tumour invasion. Int. J. Biochem. Cell Biol., 30, 1195-1202.
25. PRICE A., SHI Q., MORRIS D., WILCOX M. E., BRASHER P. M., REWCASTLE N. B., SHALINSKY D., Zou H., APPELT K., JOHNSTON R. N., YONG V. W., EDWARDS D. and FORSYTH P. (1999): Marked inhibition of tumour growth in a malignant glioma tumour model by a novel synthetic matrix metalloproteinase inhibitor AG3340. Clin. Cancer Res., 5, 845-854.
26. PRIMROSE J. N., BLEIBERG H., DANIEL F., VAN BELLE S., MANSI J. L., SEYMOUR M., JOHNSON P. W., NEOPTOLEMOS J. P., BAILLET M., BARKER K., BERRINGTON A., BROWN P. D., MILLAR A. W. and LYNCH K. P. (1999): Marimastat in recurrent colorectal cancer: exploratory evaluation of biological activity by measurement of carcinoembryonic antigen. Br. J. Cancer., 79, 509-514.
27. QIN L. X., TANG Z. Y., LI X. M., BU W. and XIA J. L. (1999): Effect of antiangiogenic agents on experimental animal models of hepatocellular carcinoma. Ann. Acad. Med., 28, 147-151.
28. ROSEMURGY A., HARRIS J., LANGLEBEN A., CASPER E., GOODE S. and RASMUSSEN H. (1999): Marimastat in patients with advanced pancreatic cancer: a dose-finding study. Am. J. Clin. Oncol., 22, 247-252.
29. SHEPHERD F. A. (1997): Alternatives to chemotherapy and radiotherapy as; adjuvant treatment for lung cancer. Lung Cancer, 17 (suppl. 1), 121-136.
30. STEWARD W. P. (1999): Marimastat (BB2516): current status of development. Cancer Chemother. Pharmacol., 43 (suppl.), 356-360.
31. TONN J. C., KERKAU S., HANKE A., BOUTERFA H., MUELLER J. G., WAGNER S., VINCE G. H. and ROOSEN K. (1999): Effect of synthetic matrix-metalloproteinase inhibitors on invasive capacity and proliferation of human malignant gliomas in vitro. Int. J. Cancer, 80, 764-772.
32. WOJTOWICZ-PRAGA S. M., DICKSON R. B. and HAWKINS M. J. (1997): Matrix rnetalloproteinase inhibitors. Invest. New Drugs, 15, 61-75.
33. WOJTOWICZ-PRAGA S., TORRI J., JOHNSON M., STEEN V., MARSHALL J., NESS E., DICKSON R., SALE M. RASMUSSEN H. S., CHIODO T. A. and HAWKINS M. J. (1998): Phase I trial of Marimastat, a novel matrix metalloprotcinase inhibitor, administered orally to patients with advanced lung cancer. J. Clin. Oncol., 16, 2150-2156.
34. YU A. E., HEWITT R. E., KLEINER D. E. and STETLER-STEVENSON W. G. (1996): Molecular regulation of cellular invasion - role of gelatinase A and TIMP-2. Biochem. Cell Biol., 74, 823-831.